Medgenics Inc. (MDGN) stock starts with “Buy” rating in note to investors by HC Wainwright

Medgenics Inc. (NASDAQ: MDGN) shares rose on Tuesday Dec 6 with lighter trade volume than normal after more analysts initiated coverage on the stock.

Meanwhile, U.S. stocks looked for direction on Tuesday with the Dow industrials trying for a fresh record a day after closing at an all-time high in the previous session.

The Dow Jones Industrial Average DJIA, -0.08% opened little-changed at 19,221, the S&P 500 index SPX, -0.01% climbed 2 points, or 0.1%, at 2,206, while the Nasdaq Composite Index COMP, +0.20%

Analysts at HC Wainwright initiated coverage on Medgenics Inc. (NASDAQ: MDGN) stock, starting the company at Buy. The company currently has a rating of Buy on the stock. As a means of comparison, a number of other analysts have issued reports on the stock in recent days, and Medgenics Inc. has secured a consensus one-year price target of $12.33, higher than the opening price of $5.20, a difference of 23.26 percent. Medgenics Inc. stock has a 52-week high of $6.79. Analysts and brokerage firms will subsequently issue periodic updates after beginning or initiating coverage. Changes in price targets are not uncommon.

Medgenics Inc. (NASDAQ: MDGN) shares last traded at $5.30, which is a jump of $0.28 or 5.58% from the previous closing price. Opening at $5.20, they varied from $5.11 and $5.45 throughout the day.

Medgenics Inc. (NASDAQ: MDGN) currently has a market cap of 196.61M.

Medgenics Inc. (NASDAQ: MDGN) Average Daily Trading Volume

145,777 shares traded hands yesterday, lower than normal, out of a total float 28,238,000. Trading volume is likely to increase in the next few days as swing traders often use swings in trading volume to determine heavy volume aggregation or distribution by institutional investors.

While increased trading for short periods will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks expresses a positive cue to market traders that institutions may be moving in, so institutional sponsorship is critical.

Institutional sponsorship simply refers to ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have teams of analysts that research thousands of stocks, so it is good validation to see them buying a stock you’re researching.

Medgenics Inc. (NASDAQ: MDGN) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

Traders can make more effective judgments on trades when they follow the trading habits of professional investors.

Trades for Medgenics Inc. (NASDAQ: MDGN) have ranged from $3.09 – 6.79, and the stock now has a 50-day MA of $5.16 and 200-day MA of $5.54. Today’s last price is 21.94%% below the 52 week high of $6.79.

Earnings growth is an important factor to consider when buying stocks and investors identify companies that have increased their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *